Venn Life Sciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Venn Life Sciences - overview
Established
2012
Location
Dublin, -, Ireland
Primary Industry
Pharmaceuticals
About
Venn Life Sciences is a consultancy firm specializing in drug development services. They provide expert solutions that facilitate the transition of pharmaceutical products from research to market authorization. Founded in 2012 in Dublin, Ireland, Venn Life Sciences operates as a consultancy firm focused on advancing drug development processes. The company has engaged in one significant deal, with Calculus Capital investing in 2012 without disclosing specific financial terms.
Tony Richardson serves as the CEO, leading the firm in its mission to support clients in the pharmaceutical and biotechnology sectors. Venn Life Sciences offers a comprehensive range of drug development consultancy services, including clinical trial design, regulatory affairs consultancy, medical writing, data management, and project management for both clinical and non-clinical developments. They work with various clients, including biotechnology firms and pharmaceutical companies, primarily across Europe and North America, ensuring tailored approaches that meet specific client requirements. In 2021, Venn Life Sciences reported revenue of USD 414,105.
80 with an EBITDA of USD -296,402. 60. Their business model revolves around B2B partnerships, providing specialized drug development services where revenue is generated through structured contracts based on the scope of services offered. As of 2012, following the investment from Calculus Capital, Venn Life Sciences aims to enhance its service offerings and expand its market presence.
The company plans to explore new geographic regions and is focused on developing additional products and services tailored to client needs. Specific details regarding upcoming products and their launch dates have not been disclosed, but the firm is committed to utilizing its resources effectively to support these growth initiatives.
Current Investors
Calculus Capital
Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceutical Research & Development
Website
https://www.vennlifesciences.com/
Company Stage
Mature - Buyout
Total Amount Raised
Subscriber access only
Venn Life Sciences - timeline of key events
Venn Life Sciences - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 391,400 | 1,933,430 | 7,447,892 | 9,217,106 | 8,553,429 | 6,059,865 | 2,939,237 | - | - | - |
| % Revenue Growth (YoY) | - | 394.0% | 285.2% | 23.8% | (7.2%) | (29.2%) | (51.5%) | - | - | - |
| EBITDA (USD) | (8,670) | (63,560) | 10,294 | (218,692) | 53,796 | 81,503 | (2,151,232) | - | - | - |
| Operating Income (USD) | (8,670) | (63,560) | 10,294 | (218,692) | (53,487) | (1,782) | (2,178,213) | - | - | - |
| Operating Margin | (2.2%) | (3.3%) | 0.1% | (2.4%) | (0.6%) | (0.0%) | (74.1%) | - | - | - |
| % EBITDA Margin | (2.2%) | (3.3%) | 0.1% | (2.4%) | 0.6% | 1.3% | (73.2%) | - | - | - |
| NET Income (USD) | (8,670) | (63,560) | 796 | 348,725 | (2,042,330) | (813,009) | (2,251,465) | - | - | - |
| % Net Margin | (2.2%) | (3.3%) | 0.0% | 3.8% | (23.9%) | (13.4%) | (76.6%) | - | - | - |
Venn Life Sciences - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Buyout | Completed | Venn Life Sciences | - |
Displaying 1 - 1 of 1
Venn Life Sciences - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.